Uncategorized
FDA receives reports of serious adverse events after triamcinolone, moxifloxacin compound injections
The FDA is warning clinicians about serious adverse events reported after intravitreal injections of triamcinolone and moxifloxacin compounded by Guardian Pharmacy Services in Dallas.At least 43 patients at two Dallas surgery centers experienced serious adverse effects after receiving the injection following cataract surgery. The FDA received the adverse event reports on April 5 and June 1.